Neuphoria Therapeutics (NEUP) Stock: Buy, Sell, or Hold?
NEUP - Neuphoria Therapeutics Inc. Common Stock
$3.47
-0.04 (-1.14%)
▼
5d:
-4.93%
30d:
-7.47%
90d:
+0.87%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When NEUP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NEUP shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NEUP shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NEUP is currently trading at $3.47, which is considered oversold relative to its 30-day fair value range of $3.62 to $3.80.
Technical Outlook: Technically, NEUP is showing support break momentum. The price is currently testing key support at $3.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NEUP scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+101.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NEUP is showing support break momentum. The price is currently testing key support at $3.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: NEUP scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+101.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.62 -
$3.80
Company Quality Score
26/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (21/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 101.7% below Wall St target ($7.00)
- WARNING: Composite score 26/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.62 -
$3.80
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.45
Resistance Level
$3.79
Current Trend
Support Break
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.43
Wall Street Target
$7.00
(+101.7%)
Share & Embed Analysis
Last updated: October 03, 2026 11:25 PM ET
Data refreshes hourly during market hours. Next update: 12:25 AM
Data refreshes hourly during market hours. Next update: 12:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEUP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 52 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 46 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
